Pharmacology of Drugs for Peptic Ulcer

Introduction/Overview

Peptic ulcer disease (PUD) represents a common clinical condition characterized by a breach in the mucosal lining of the stomach or duodenum, extending through the muscularis mucosae. The pathophysiology involves an imbalance between aggressive factors, primarily gastric acid and pepsin, and defensive mucosal mechanisms. The pharmacological management of PUD has undergone a significant evolution, shifting from acid suppression as the sole therapeutic goal to a more nuanced approach that includes eradication of Helicobacter pylori (H. pylori) infection and enhancement of mucosal defense. This paradigm shift has markedly reduced the incidence of complications such as hemorrhage and perforation and has decreased the need for surgical intervention.

The clinical relevance of understanding the pharmacology of anti-ulcer drugs extends beyond the treatment of uncomplicated ulcers. These agents are widely employed in the management of gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and as prophylactic therapy in patients at risk for stress-related mucosal damage or nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathy. Mastery of their mechanisms, pharmacokinetic profiles, and adverse effect spectra is therefore essential for rational prescribing across multiple clinical scenarios.

Learning Objectives

• Classify the major drug categories used in the treatment and prevention of peptic ulcer disease, including their chemical and pharmacological distinctions.
• Explain the molecular and cellular mechanisms of action for each drug class, detailing their effects on acid secretion, mucosal integrity, and bacterial eradication.
• Analyze the pharmacokinetic properties of these agents, including absorption characteristics, metabolic pathways, and implications for dosing in special populations.
• Evaluate the therapeutic applications, major adverse effects, and significant drug interactions associated with anti-ulcer pharmacotherapy.
• Formulate appropriate treatment and prophylaxis strategies for peptic ulcer disease based on etiology, patient comorbidities, and concurrent medications.

Classification

Drugs used in the management of peptic ulcer disease can be systematically classified based on their primary mechanism of action. This classification provides a framework for understanding their therapeutic roles and clinical applications.

Acid-Suppressing Agents

This category comprises drugs that directly or indirectly reduce the secretion of hydrochloric acid by gastric parietal cells.

• Proton Pump Inhibitors (PPIs): Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole, Dexlansoprazole. These are substituted benzimidazoles that covalently inhibit the H⁺/K⁺-ATPase pump.
• Histamine H₂-Receptor Antagonists (H2RAs): Cimetidine, Ranitidine, Famotidine, Nizatidine. These agents competitively inhibit histamine binding at the H₂ receptor on parietal cells.

Mucosal Protectants and Prostaglandin Analogues

These drugs enhance mucosal defense mechanisms rather than suppressing acid.

• Prostaglandin Analog: Misoprostol (a synthetic PGE₁ analogue).
• Coating Agents: Sucralfate (a complex salt of sucrose octasulfate and aluminum hydroxide).
• Bismuth-Containing Compounds: Bismuth subsalicylate, colloidal bismuth subcitrate.

Antacids

These are basic compounds that neutralize secreted gastric acid. Common agents include aluminum hydroxide, magnesium hydroxide, calcium carbonate, and sodium bicarbonate. They are often used for symptomatic relief.

Agents for Helicobacter pylori Eradication

H. pylori eradication requires combination therapy, typically involving multiple antimicrobials alongside an acid-suppressing agent to enhance antibiotic efficacy.

• First-line Regimens: Commonly include a PPI or H2RA combined with two or three antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, or levofloxacin.
• Bismuth-based Quadruple Therapy: Incorporates a bismuth compound, a PPI, tetracycline, and metronidazole.

Mechanism of Action

The mechanisms by which anti-ulcer drugs exert their therapeutic effects are diverse, targeting different points in the pathophysiology of ulcer formation.

Proton Pump Inhibitors

PPIs are prodrugs that require activation in the acidic environment of the secretory canaliculus of the parietal cell. In their inactive form, they are lipophilic weak bases that diffuse across membranes into the parietal cell. Within the highly acidic (pH < 4) secretory canaliculus, they undergo protonation and are converted to reactive sulfenamide or sulfenic acid intermediates. These activated forms form irreversible, covalent disulfide bonds with cysteine residues on the extracellular domain of the H⁺/K⁺-ATPase (the proton pump). This enzyme is the final common pathway for acid secretion, exchanging cytoplasmic H⁺ for luminal K⁺. Inhibition is irreversible, and acid secretion resumes only after synthesis of new pump molecules, a process with a half-life of approximately 24-48 hours. This results in profound and prolonged suppression of both basal and stimulated acid secretion.

Histamine H₂-Receptor Antagonists

H2RAs act as competitive antagonists at the histamine H₂ receptor located on the basolateral membrane of the gastric parietal cell. Histamine, released from enterochromaffin-like (ECL) cells, is a potent stimulator of acid secretion via this receptor, which is coupled to a G_s protein. Receptor activation increases intracellular cyclic AMP (cAMP), which activates protein kinase A and ultimately stimulates the H⁺/K⁺-ATPase. By blocking this pathway, H2RAs suppress acid secretion stimulated by histamine, and to a lesser extent, by gastrin and acetylcholine, as these secretagogues also exert part of their effect via histamine release. Their inhibition is reversible, leading to a shorter duration of action compared to PPIs.

Antacids

Antacids are simple bases that directly neutralize secreted hydrochloric acid in the gastric lumen, raising the intragastric pH. The neutralization reaction can be generalized as: Base + HCl → Salt + H₂O. The increase in pH also reduces the proteolytic activity of pepsin, which is optimal at pH 1.5-3.5. Some antacids, notably aluminum-containing preparations, may provide additional effects by adsorbing bile salts and pepsin and stimulating prostaglandin synthesis and mucosal bicarbonate secretion.

Misoprostol

Misoprostol is a synthetic analogue of prostaglandin E₁. It exerts its protective effects through binding to specific prostaglandin receptors on gastric epithelial cells. Receptor activation stimulates several protective mechanisms: increased secretion of mucus and bicarbonate, which forms a protective gel layer; enhanced mucosal blood flow, improving nutrient delivery and removal of damaging agents; and possibly a direct inhibition of parietal cell acid secretion via suppression of histamine-stimulated cAMP formation. Its primary clinical role is the prevention of NSAID-induced gastric and duodenal ulcers.

Sucralfate

Sucralfate is a complex of sucrose octasulfate and aluminum hydroxide. In the acidic environment of the stomach, it undergoes polymerization and cross-linking to form a viscous, adhesive paste that selectively binds to proteins at the base of ulcers and erosions, creating a physical barrier that lasts for several hours. This barrier protects the damaged mucosa from further injury by acid, pepsin, and bile salts. Additionally, sucralfate may stimulate local prostaglandin production, increase mucosal bicarbonate secretion, and bind epidermal growth factor, concentrating it at the ulcer site to promote healing.

Bismuth Compounds

Bismuth subsalicylate and subcitrate have multiple actions. They exert weak antacid properties and form a protective coating over ulcer craters. More importantly, they possess direct antimicrobial activity against H. pylori. Bismuth disrupts the bacterial cell wall, inhibits enzymatic activities including urease (which is crucial for the bacterium’s survival in the acidic stomach), and prevents adhesion of the bacteria to the gastric epithelium. The salicylate moiety may contribute anti-inflammatory effects.

Pharmacokinetics

The pharmacokinetic profiles of anti-ulcer drugs significantly influence their dosing regimens, onset of action, and potential for drug interactions.

Proton Pump Inhibitors

Absorption: PPIs are acid-labile prodrugs formulated as enteric-coated granules or tablets to prevent degradation in the stomach. Absorption occurs in the small intestine, but bioavailability is often variable and incomplete due to first-pass metabolism. Bioavailability may increase with repeated dosing as acid suppression reduces their degradation. They should be administered 30-60 minutes before a meal to coincide with activation of proton pumps.

Distribution: PPIs are highly protein-bound (>95%) and have a relatively small volume of distribution. They concentrate in the acidic compartment of parietal cells.

Metabolism: Extensive hepatic metabolism occurs primarily via the cytochrome P450 system, specifically CYP2C19 and CYP3A4. Genetic polymorphisms in CYP2C19 can lead to significant interindividual variability in plasma levels and acid-suppressive effect, classifying patients as poor, intermediate, extensive, or ultra-rapid metabolizers.

Excretion: Metabolites are primarily excreted in the urine, with a small fraction in bile. The plasma elimination half-life is short (1-2 hours), but the pharmacodynamic effect on acid secretion lasts 24 hours or more due to irreversible pump inhibition.

Histamine H₂-Receptor Antagonists

Absorption: H2RAs are generally well absorbed after oral administration, with bioavailabilities ranging from 40-50% for cimetidine to over 90% for famotidine. Food may delay but does not significantly reduce absorption.

Distribution: They distribute widely throughout the body, crossing the placenta and entering breast milk. Protein binding is relatively low (15-20%).

Metabolism: Hepatic metabolism varies: cimetidine and ranitidine undergo significant metabolism via CYP450 enzymes, while famotidine and nizatidine undergo minimal hepatic transformation, with the majority of the dose excreted unchanged in urine.

Excretion: Renal excretion is the primary route of elimination for most H2RAs and their metabolites. The elimination half-life ranges from 1.5-4 hours, necessitating multiple daily doses for continuous acid suppression, although longer-acting formulations exist.

Misoprostol

Absorption: Rapidly absorbed after oral administration and undergoes extensive first-pass de-esterification to its active free acid metabolite.

Distribution: The active metabolite is highly protein-bound (>80%).

Metabolism and Excretion: Further metabolized via fatty acid oxidation pathways. Metabolites are excreted primarily in the urine, with a terminal half-life of approximately 20-40 minutes for the active metabolite.

Sucralfate

Absorption: Minimal systemic absorption (<5% of the aluminum content). Its action is entirely local within the gastrointestinal tract.

Distribution, Metabolism, Excretion: As it is not absorbed, systemic pharmacokinetics are not applicable. The unabsorbed complex is excreted in the feces.

Antacids

Antacids are minimally absorbed, acting locally in the gastric lumen. However, a fraction of their cationic components (Al³⁺, Mg²⁺, Ca²⁺) can be absorbed, which has implications for systemic toxicity with chronic overuse. Onset of action is rapid (minutes), but duration is short (1-2 hours) depending on gastric emptying.

Therapeutic Uses/Clinical Applications

The selection of an anti-ulcer agent is guided by the underlying etiology of the ulcer, desired speed of healing, and need for prophylaxis.

Peptic Ulcer Disease

• Duodenal Ulcers: First-line therapy involves eradication of H. pylori if present, typically with a PPI-based triple therapy (PPI + clarithromycin + amoxicillin or metronidazole) for 10-14 days, followed by continued acid suppression with a PPI for 4-8 weeks if the ulcer was large or complicated. For H. pylori-negative ulcers, PPIs are the agents of choice for healing.
• Gastric Ulcers: Management is similar, though the duration of subsequent acid-suppressive therapy may be longer (6-8 weeks), and follow-up endoscopy is often recommended to confirm healing and rule out malignancy.

Helicobacter pylori Eradication

This is a cornerstone of PUD therapy where infection is confirmed. Standard first-line regimens include:

1. Clarithromycin-based Triple Therapy: PPI + clarithromycin + amoxicillin (or metronidazole if penicillin-allergic) for 14 days.
2. Bismuth Quadruple Therapy: PPI + bismuth subsalicylate/subcitrate + tetracycline + metronidazole for 10-14 days. This is often used as first-line in regions with high clarithromycin resistance or as second-line salvage therapy.
3. Concomitant Therapy: PPI + clarithromycin + amoxicillin + metronidazole for 10-14 days.
4. Sequential Therapy: A 10-day regimen starting with a PPI + amoxicillin for 5 days, followed by a PPI + clarithromycin + metronidazole for 5 days.

Eradication rates are highly dependent on local antibiotic resistance patterns.

Gastroesophageal Reflux Disease

PPIs are the most effective pharmacologic agents for healing erosive esophagitis and providing symptomatic relief in GERD. H2RAs are used for milder, intermittent symptoms. Therapy is often long-term, with the lowest effective dose used for maintenance.

Prevention of NSAID-Induced Ulcers

For patients requiring chronic NSAID therapy who are at high risk (history of ulcer, advanced age, concomitant corticosteroids or anticoagulants), co-therapy with a PPI or misoprostol is recommended. PPIs are generally preferred due to better tolerability. Misoprostol is highly effective but limited by its side effect profile, particularly diarrhea and abdominal cramps.

Stress Ulcer Prophylaxis

In critically ill patients (e.g., those on mechanical ventilation, with coagulopathy), PPIs or H2RAs are used to prevent clinically significant bleeding from stress-related mucosal damage. The benefit must be weighed against potential risks, such as an increased incidence of Clostridioides difficile infection and pneumonia.

Zollinger-Ellison Syndrome

This gastrin-secreting tumor causes profound gastric acid hypersecretion. High-dose PPIs are the treatment of choice for long-term management, often at doses twice the standard or more, administered twice daily.

Adverse Effects

While generally well-tolerated, anti-ulcer drugs are associated with a range of adverse effects, from common and mild to rare and serious.

Proton Pump Inhibitors

Common: Headache, diarrhea, nausea, abdominal pain, and flatulence. These are usually mild and self-limiting.

Long-term/Serious Concerns:

• Nutritional Deficiencies: Chronic use may impair absorption of vitamin B₁₂, magnesium (leading to hypomagnesemia), iron, and possibly calcium.
• Increased Infection Risk: Hypochlorhydria may predispose to enteric infections (e.g., Salmonella, Campylobacter), community-acquired pneumonia, and Clostridioides difficile-associated diarrhea.
• Bone Health: Long-term, high-dose use has been associated with a modest increase in the risk of hip, wrist, and spine fractures, possibly related to calcium malabsorption.
• Renal Effects: Cases of acute interstitial nephritis, though rare, have been reported.
• Dementia Risk: Some observational studies suggest a potential association, but causality remains unproven and controversial.
• Rebound Acid Hypersecretion: Sudden discontinuation after prolonged use can lead to symptomatic rebound, potentially driving chronic use.

Histamine H₂-Receptor Antagonists

Common: Generally well-tolerated. Side effects may include headache, dizziness, diarrhea, or constipation.

Specific Agent Concerns:

• Cimetidine: Has antiandrogenic effects (gynecomastia, impotence with long-term high doses) and is a potent inhibitor of cytochrome P450 enzymes.
• Ranitidine: Previously available formulations were found to contain low levels of N-nitrosodimethylamine (NDMA), a probable human carcinogen, leading to its withdrawal from many markets.
• CNS Effects: Mental confusion, agitation, and hallucinations are rare, occurring primarily in elderly or severely ill patients, likely due to H₂ receptor blockade in the brain.

Misoprostol

The most frequent adverse effects are dose-related gastrointestinal disturbances: abdominal pain, diarrhea, and cramping. These can be mitigated by taking the drug with food and starting at a low dose. Uterine contractions are a pharmacologic effect, making it contraindicated in pregnancy due to the risk of abortion or premature birth. Nausea and vomiting may also occur.

Sucralfate

Constipation is the most common side effect (2-3%). Due to its aluminum content, there is a potential risk of aluminum accumulation and toxicity in patients with renal failure. It can cause bezoar formation in patients with delayed gastric emptying. Hypophosphatemia has been reported rarely with chronic use.

Antacids

Side effects are primarily related to the cationic components:

• Aluminum-containing: Constipation, hypophosphatemia, and with renal impairment, aluminum toxicity (osteomalacia, encephalopathy).
• Magnesium-containing: Diarrhea, and with renal impairment, hypermagnesemia (leading to muscle weakness, arrhythmias).
• Calcium carbonate: Rebound acid secretion, constipation, hypercalcemia, and milk-alkali syndrome with chronic overuse.
• Sodium bicarbonate: Systemic alkalosis, sodium overload, and rebound acid secretion.

Drug Interactions

Significant drug interactions can occur with anti-ulcer agents, primarily mediated through alterations in gastric pH affecting drug absorption, or via effects on hepatic metabolism.

pH-Dependent Absorption Interactions

Elevated gastric pH can significantly alter the absorption of drugs that require an acidic environment for dissolution or absorption.

• Decreased Absorption: PPIs and H2RAs can reduce the bioavailability of drugs such as ketoconazole, itraconazole, iron salts (ferrous sulfate), and atazanavir (an HIV protease inhibitor).
• Increased Absorption: The absorption of weak bases like digoxin may be increased due to enhanced dissolution at higher pH.

Administration of affected drugs several hours before the acid-suppressing agent may mitigate some interactions.

Metabolism-Based Interactions

Cimetidine: Is a potent non-selective inhibitor of several cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2D6, CYP3A4). It can increase the plasma concentrations of a wide array of drugs metabolized by these pathways, including warfarin, phenytoin, theophylline, certain benzodiazepines, and tricyclic antidepressants. Other H2RAs have much weaker or negligible effects on CYP450.

PPIs: Primarily metabolized by CYP2C19 and CYP3A4, they can act as competitive inhibitors. Omeprazole and esomeprazole are moderate inhibitors of CYP2C19 and may increase levels of drugs like clopidogrel (a prodrug activated by CYP2C19), potentially reducing its antiplatelet efficacy. This interaction is less pronounced with pantoprazole, rabeprazole, and lansoprazole. PPIs may also interact with drugs like methotrexate, potentially increasing its toxicity by competing for renal tubular secretion.

Other Notable Interactions

• Sucralfate: Can bind to other drugs in the GI tract (e.g., tetracyclines, fluoroquinolones, phenytoin, warfarin, levothyroxine), forming non-absorbable complexes. Other medications should be taken at least 2 hours apart from sucralfate.
• Antacids: Similar binding interactions occur with tetracyclines and fluoroquinolones. Cationic components (Al³⁺, Mg²⁺, Ca²⁺) can chelate with these antibiotics, drastically reducing their absorption.
• Misoprostol: Antacids containing magnesium may exacerbate misoprostol-induced diarrhea.

Special Considerations

The use of anti-ulcer drugs requires careful adjustment in specific patient populations due to altered pharmacokinetics, pharmacodynamics, or safety profiles.

Pregnancy and Lactation

Pregnancy:

• PPIs: Generally considered low risk. Large epidemiological studies have not shown a consistent pattern of major teratogenicity. They are often used when clearly needed.
• H2RAs: Famotidine and ranitidine (prior to NDMA concerns) are often preferred. Cimetidine’s antiandrogenic effects warrant caution.
• Misoprostol: Absolute contraindication due to its uterotonic effects, which can cause abortion or premature labor.
• Sucralfate: Considered safe as it is poorly absorbed.
• Antacids: Calcium carbonate and magnesium hydroxide are generally acceptable; sodium bicarbonate and high-dose aluminum hydroxide should be avoided.

Lactation: Most agents are excreted in breast milk in small amounts. PPIs and H2RAs are generally considered compatible with breastfeeding, though cimetidine may be avoided due to theoretical antiandrogenic effects on the infant.

Pediatric Considerations

PPIs and H2RAs are used in children for GERD and PUD. Dosing is typically weight-based. Liquid formulations are available for many agents. Long-term safety data in children is more limited than in adults, and the lowest effective dose for the shortest duration should be employed. Sucralfate is rarely used in young children due to the risk of aluminum accumulation and constipation.

Geriatric Considerations

Elderly patients are more susceptible to certain adverse effects. They may be at higher risk for C. difficile infection, pneumonia, and fractures associated with long-term PPI use. Age-related decline in renal function increases the risk of toxicity from aluminum (sucralfate, antacids) and magnesium (antacids), and necessitates dose adjustment for renally excreted H2RAs like famotidine. CNS side effects from H2RAs are more common in this population.

Renal Impairment

Dosage adjustment is generally not required for PPIs. For H2RAs, particularly famotidine and nizatidine which are predominantly renally excreted, dose reduction is necessary to prevent accumulation. Cimetidine and ranitidine doses may also need adjustment. Sucralfate and aluminum-containing antacids are contraindicated in significant renal impairment due to the risk of aluminum toxicity. Magnesium-containing antacids should be avoided due to risk of hypermagnesemia.

Hepatic Impairment

PPIs metabolized by the liver (all current agents) may have reduced clearance in severe hepatic disease, but dosage adjustment is rarely needed. For H2RAs, caution is advised with cimetidine and ranitidine; famotidine may be preferred as its metabolism is less dependent on hepatic function. Monitoring for signs of CNS toxicity is prudent.

Summary/Key Points

• The pharmacology of peptic ulcer drugs encompasses agents that suppress gastric acid (PPIs, H2RAs), neutralize acid (antacids), enhance mucosal defense (misoprostol, sucralfate), and eradicate H. pylori (antibiotic combinations).
• PPIs provide the most profound and sustained acid suppression via irreversible inhibition of the H⁺/K⁺-ATPase, making them first-line for healing severe erosive disease and for H. pylori eradication regimens.
• H2RAs offer reversible, competitive blockade of parietal cell H₂ receptors, effective for milder acid-related conditions and nocturnal acid breakthrough.
• The therapeutic approach to PUD is etiology-driven: H. pylori-positive ulcers require eradication therapy; NSAID-induced ulcers require discontinuation of the offending agent and/or co-therapy with a PPI or misoprostol.
• Significant adverse effect profiles must be considered: long-term PPI use is associated with nutritional deficiencies, infection risks, and possible bone effects; misoprostol causes dose-limiting GI effects and is abortifacient; antacids and sucralfate have cation-specific toxicities.
• Major drug interactions occur via pH-dependent alterations in absorption (e.g., ketoconazole, iron) and inhibition of cytochrome P450 enzymes (notably by cimetidine and some PPIs like omeprazole).
• Special populations require tailored therapy: avoidance of misoprostol in pregnancy, dose adjustment in renal impairment for renally excreted drugs, and caution regarding aluminum/magnesium in renal failure and the elderly.

Clinical Pearls

• For optimal effect, PPIs should be administered 30-60 minutes before the first meal of the day to activate during the post-prandial acid secretory surge.
• When testing for H. pylori via urea breath test or stool antigen, PPIs should be discontinued for 2 weeks and H2RAs for 24-48 hours prior to avoid false-negative results.
• In patients on clopidogrel, if a PPI is necessary for GI protection, pantoprazole or lansoprazole may be preferred over omeprazole or esomeprazole due to a weaker CYP2C19 interaction, though the clinical significance of this interaction remains debated.
• “Step-down” therapy—using a PPI for initial ulcer healing followed by maintenance with an H2RA or on-demand PPI—can be a strategy to minimize long-term PPI exposure.
• Always consider and document the indication when initiating long-term acid-suppressive therapy, and periodically re-evaluate the need for continued treatment.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.